Steven Roy, MBA
President and CEO, Board of Directors
Tel: (970) 632-2200
Mr. Roy has served as President & CEO of VetDC since 2010. Previously, he served as Director of Licensing at Amgen, Inc. (NASDAQ – AMGN, an international biopharmaceutical company) where he played roles in Business Development, Marketing and Licensing from 1994 to 2007. Mr. Roy headed up Strategy, Planning and Operations for the launch of a multi-billion dollar cancer therapeutic and created and led Amgen’s Department of Alliance Management, representing 70 collaborations and over $100M in annual R&D expenditure. Mr. Roy began his career as a Laboratory Supervisor at Ligand Pharmaceuticals, Inc. (NASDAQ – LGND) from 1988 to 1992 where he implemented Ligand’s high-throughput screening program. Steven earned a BA in Molecular Biology from the University of California, San Diego and an MBA from the University of Michigan.
Ann R. Donoghue, DVM, MS
Senior Director, Product Development & Regulatory Affairs
Tel: (970) 632-2200
Dr. Ann Donoghue has over 20 years of drug development experience and has been involved in all aspects of new drug and diagnostic test development. She has led project teams to approval of USDA licensed diagnostic test kits, an EPA registered pesticide and New Animal Drug Applications. Her most recent role has provided her with experience in human health pharmaceuticals, from project initiation through scale up to commercial GMP manufacturing. She co-led a successful FDA pre-approval inspection of a new GMP manufacturing facility; she has conducted GLP study site audits and has been the Sponsor Monitor for several GCP clinical trials. Her teams achieved an Orphan Drug Designation and completed a subsequent Investigational New Drug Application resulting in a successful Phase I clinical trial in less than one year from project initiation. Ann has participated in product development regulatory strategy and in face-to-face predevelopment conferences with the FDA and EPA. She has developed, written and instituted controlled document systems for GLP, GCP and GMP compliance. These experiences have provided broad project management knowledge spanning early research to finished product marketing.
Dr. Donoghue received her Bachelor of Science (Animal Science), Doctor of Veterinary Medicine and Master of Science (Large Animal Clinical Sciences – Parasitology) degrees from Michigan State University. She served as the Chief of Parasitology section of the MSU Animal Health Diagnostic Laboratory. Her employment has been with Hoechst-Roussel Agri-Vet Company, Heska Corporation and PR Pharmaceuticals, Inc. She is a regular reviewer for the Journal of the American Veterinary Medical Association and the American Journal of Veterinary Research and has been an invited continuing education speaker at 2 national veterinary conferences.
Douglas G. Johnson, Ph.D.
Senior Director, Pharmaceutical Operations
Tel: (970) 632-2200
Dr. Douglas G. Johnson, Ph.D. has more than 20 years of experience in the pharmaceutical industry and is currently president of OCAM Solutions, a synthetic molecule drug development advisory company covering all areas of CMC activities. Prior to founding OCAM Solutions, Doug Johnson spent over 10 years as Vice President of Manufacturing and Vice President of Pharmaceutical Sciences at Allos Therapeutics, managing and integrating all outsourced chemistry and manufacturing activities for a virtual company focused on small organic molecules for oncology applications. He is experienced in both drug substance and drug product elements of development. Dr. Johnson has been involved in the preparation of several NDAs and numerous INDs.
In addition to his experience at Allos, Doug Johnson spent over 8 years with Baxter Healthcare. He has extensive experience in formulation (three NDAs), drug development (two INDs), product support and manufacturing. He has four formulation patents, with two resulting in marketed products. Doug has a Ph.D. in Organic Chemistry from the University of Minnesota, Minneapolis and did his Post-Doctoral work at the University of Chicago. Furthermore, Doug was a laser spectroscopist in the artificial photosynthesis group at Argonne National Laboratory.
Douglas H. Thamm, VMD, DACVIM (Oncology)
Head of Clinical Development
Dr. Thamm is an Associate Professor and Barbara Cox Anthony Chair in Oncology and the Director of Clinical Research at the Colorado State University Animal Cancer Center. He is also a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University. Dr. Thamm received his Bachelor’s and V.M.D. degrees from the University of Pennsylvania. He completed a Residency in Medical Oncology at the University of Wisconsin, and was a researcher there for 5 additional years before joining the faculty at CSU in 2004. He is the author of over 80 peer-reviewed publications in veterinary and basic cancer research, has been Oncology Section Editor for the most recent 2 editions of Kirk’s Veterinary Therapy and is Co-Editor-In-Chief of the journal Veterinary and Comparative Oncology. His clinical and research interests include novel targeted therapies for animal and human cancer and ways to integrate these therapies with existing treatment. He has conducted over 24 animal cancer trials and was one of the lead veterinary investigators on TANOVEA®-CA1 (rabacfosadine). Dr. Thamm is an internationally recognized veterinary cancer opinion leader.
Terry Opgenorth, Ph.D.
Chief Scientific Officer, Board Observer
Dr. Opgenorth serves as Vice President of CSU Ventures and Executive Director, NewCo Launchpad. He retired from Abbott Laboratories (now AbbVie) in 2007, where he was Divisional Vice President of Metabolic Disease Research, Antiviral Research and Target-Lead Discovery Research for Abbott’s Global Pharmaceutical Research and Development Division. At Abbott he championed a number of biotechnology collaborations, and led teams that advanced multiple drug candidates into clinical development. Dr. Opgenorth serves as a Director on Boards for KromaTiD, MonImmune, Vidasym, and Cetya. Along with being founder and CSO of VetDC, he was CEO of Vidasym, Inc., a discovery company developing drugs for treatment of human chronic kidney disease. He holds a BA in Biology from Calvin College, and MS and PhD degrees in Physiology from University of Illinois-Urbana.
Cathy Gust, Ph.D.
Dr. Gust has more than 20 years of experience leading teams through the development and commercialization processes in the biotech, pharmaceutical, and diagnostic industries. Her experience spans all phases of development (preclinical through launch) in both R&D and Manufacturing. Prior to joining VetDC, Dr. Gust worked at Amgen Inc., a biopharmaceutical company. Her accomplishments include leading the launch readiness team to introduce two devices into Amgen’s largest phase 3 clinical program, providing global program management for Amgen’s first small molecule, and building the Corporate Operations Global Program Management Office to deliver results for Manufacturing’s priority, cross-site, cross-functional programs. In addition to her experience at Amgen, Dr. Gust developed diagnostic immunoassays for infectious diseases at both Ortho Clinical Diagnostics (Johnson & Johnson) and Baxter Diagnostics (Baxter Healthcare Corporation). She holds a BS degree in Animal Science from Colorado State University, MS and PhD degrees in Reproductive Physiology from West Virginia University and did her post-doctoral work at Eli Lilly.